Immuno-oncology technology最新文献_第9页

112P Preclinical characterization of TOOLBOX-enhanced CTC127-T cells targeting MAGE-A4a and preparation for a first-in-human phase I trial in solid tumors 针对MAGE-A4a的toolbox增强CTC127-T细胞的临床前特征和实体瘤的首次人体I期临床试验的准备

Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101197

A. Busse , A.S. Japp , E. Tregel , I. Edes , J. Clauß , R. Stahn , N. Nussbaum , G. Hernandez , S. Stadler , U. Keller , F. Lorenz

引用次数: 0

107P Engineering CAR T cell therapy through novel co-stimulatory domains 通过新的共刺激结构域工程CAR - T细胞治疗

Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101192

H.N. Aksoy Kilinc, V. Pitic, H.T.C. Chan, A. Al-Shamkhani, A. Roghanian

引用次数: 0

88P INVENT4GB: Non-viral DNA vector-engineered TCR-T cell therapy for glioblastoma 非病毒DNA载体工程TCR-T细胞治疗胶质母细胞瘤

Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101173

K. Sanghvi , S. Rizzato , M. Stenzinger , Y-C. Chih , E. Green , I. Poschke , M. Kratzmann , R. Harbottle , A. Benner , P. Schmidt , S. Eichmüller , J. Steinbach , L. Bullinger , P. Vajkoczy , G. Tabatabai , W. Wick , H. Boenig , M. Platten , L. Bunse

引用次数: 0

50P DLL3 expression by immunohistochemistry in rare neuroendocrine neoplasms and associated response to off label tarlatamab 罕见神经内分泌肿瘤中50P DLL3的免疫组化表达及对非标塔拉他单抗的相关反应

Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101133

T. Schieber , J. Hobbs , J. Campaign-Mauser , E. Jones , A. Olinger , B. Bortka , B. Gustafson , S. Blocker , D. Kim , S. Mullangi , M.R. Lekkala , C.H. Huang , R. Parikh , P. Neupane , J. Zhang , H. Li

引用次数: 0

38P Integrin αvβ6 and PD-L1 expression and their correlation with clinicopathological features in Thai patients with cholangiocarcinoma 泰国胆管癌患者38P整合素αvβ6、PD-L1表达及其与临床病理特征的相关性

Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101121

S. Buadee , W. Jirasuviboon , C. Somboonpatarakun , K. Suwanchiwasiri , N. Phanthaphol , M. Junking , P-T. Yenchitsomanus

引用次数: 0

64P Artificial intelligence (AI) tools established for the optimization of immunotherapy of cancer 建立64P人工智能（AI）工具，优化癌症免疫治疗

Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101147

A.A. Tarhini, P. Dave, I. El Naqa

引用次数: 0

7P MTAP-deletion and correlation with tumor microenvironment in resected stage IIIpN2-NSCLC: A LungART trial substudy 在切除的iii期ipn2 - nsclc中，7P mtap缺失及其与肿瘤微环境的相关性：LungART试验亚研究

Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101092

D. Diaz-Jimenez , M.R. Ghigna , V.M. Albarran Artahona , A. Lopez Gutierrez , J. Adam , M. Aldea , J-P. Dales , G. Granier , N. Cozic , F. Barlesi , D. Planchard , A. Levy , C. Le Pechoux , B. Besse , J. Remon Masip

引用次数: 0

Ligand-receptor interactions of V-domain Ig-containing suppressor of T cell activation and programmed death-1 suppress the anticancer activities of T cells T细胞活化抑制因子和程序性死亡-1的配体与受体相互作用抑制T细胞的抗癌活性

Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-11-13 DOI: 10.1016/j.iotech.2025.101533

M. Abooali , X. Lei , I.M. Yasinska , S. Schlichtner , R. Hussain , G. Siligardi , T.-M. Gianga , S.M. Berger , D. Cholewa , B.F. Gibbs , E. Fasler-Kan , V.V. Sumbayev

{"title":"Ligand-receptor interactions of V-domain Ig-containing suppressor of T cell activation and programmed death-1 suppress the anticancer activities of T cells","authors":"M. Abooali , X. Lei , I.M. Yasinska , S. Schlichtner , R. Hussain , G. Siligardi , T.-M. Gianga , S.M. Berger , D. Cholewa , B.F. Gibbs , E. Fasler-Kan , V.V. Sumbayev","doi":"10.1016/j.iotech.2025.101533","DOIUrl":"10.1016/j.iotech.2025.101533","url":null,"abstract":"<div><h3>Background</h3><div>V-domain immunoglobulin-containing suppressor of T cell activation (VISTA) is a unique multifunctional immune checkpoint protein, which can display both receptor and ligand properties. It plays a crucial role in the cancer immune evasion machinery operated by a wide range of human malignancies and may thus be considered as a potential target for immunotherapy of cancer. Receptors of VISTA through which this protein transmits immunosuppressive signals under various normal and pathological conditions remain to be identified.</div></div><div><h3>Materials and methods</h3><div>To conduct the study, we used human recombinant proteins and various human cell lines as well as primary T cells. A wide range of techniques including tissue culture and co-cultures, Western blot analysis, on-cell Western, ELISA, co-immunoprecipitation, biochemical assays and synchrotron radiation circular dichroism spectroscopy were employed.</div></div><div><h3>Results</h3><div>Here we report for the first time that VISTA has affinity to programmed cell death protein 1 (PD-1) and binds it as a ligand. We found that when interacting with PD-1, VISTA suppresses interleukin 2 production by T helper cells. These effects were confirmed in the <em>in vitro</em> and <em>ex vivo</em> experiments. Affinity of VISTA to PD-1 was also characterised and found to be moderate, with a <em>K</em><sub>d</sub> of ∼2.3 μM detected by synchrotron radiation circular dichroism spectroscopy.</div></div><div><h3>Conclusions</h3><div>These results open a completely new chapter in our understanding of the concept of immune checkpoint proteins, where some of them clearly show both ligand and receptor activities and display multifunctional properties.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101533"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145748242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Protein engineering to overcome limitations of key cytokines in cancer immunotherapy: current approaches and future perspectives 蛋白质工程克服癌症免疫治疗中关键细胞因子的限制：目前的方法和未来的展望

Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-06-21 DOI: 10.1016/j.iotech.2025.101064

U. Salazar , P. Cioffi , B. Taskoparan , I. Moraga , S. Mitra , J. vom Berg

{"title":"Protein engineering to overcome limitations of key cytokines in cancer immunotherapy: current approaches and future perspectives","authors":"U. Salazar , P. Cioffi , B. Taskoparan , I. Moraga , S. Mitra , J. vom Berg","doi":"10.1016/j.iotech.2025.101064","DOIUrl":"10.1016/j.iotech.2025.101064","url":null,"abstract":"<div><div>Given their central role in immune regulation, cytokines have long been considered attractive therapeutic agents, particularly in cancer immunotherapy. Despite a strong preclinical and clinical rationale, only a limited number of cytokines have been approved for cancer immunotherapy to date, and their clinical use often remains limited to specialized centers. Here we briefly review the biological traits that make some of the most widely studied cytokines—specifically, interleukin (IL)-2, IL-15, and IL-12—attractive for immunotherapy and, conversely, the challenges encountered during their clinical translation. Focusing on these three cytokines in the context of systemic or local delivery, we highlight protein engineering strategies that address challenges to increase their therapeutic index, such as poor tolerability, short serum half-life, and pleiotropy. For systemic delivery, these strategies include the use of shielded cytokines and immunocytokines to elicit tissue context-dependent activity by taking advantage of unique characteristics of the tumor microenvironment (TME). Half-life extension domains to increase serum prevalence, partial agonism to restrict activity to intended effector cells, and <em>cis</em>-targeting are also discussed. For local administration, we review protein modifications intended to increase prevalence in the tumor, including increased size, adhesion to the extracellular matrix, targeting tumor-associated antigens, or targeting immune effector cells in the TME. Looking ahead, we anticipate the development of novel approaches such as reversible, context-dependent switches, and an increasing number of combinations of individual modifications.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101064"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145128268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

113P CTO1681 attenuates CRS-driving cytokines without compromising CAR T cell-mediated tumor killing in vitro 113P CTO1681在体外不影响CAR - T细胞介导的肿瘤杀伤的情况下减弱crs驱动细胞因子

Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101198

M. Howell , J. Craigo , M. Frigault , N. Todd , T. Whalen

引用次数: 0